CMG190303

CMG190303 is a Phase 3 fixed-dose combination of two already-approved generic drugs, dapagliflozin (an SGLT2 inhibitor that lowers blood sugar by making the kidneys excrete glucose in urine) and rosuvastatin (a statin that cuts LDL cholesterol), being tested by South Korea's CMG Pharmaceutical (KRX: 058820) in 240 patients with both type 2 diabetes and dyslipidemia [1]. This is a lifecycle and convenience play, not a new molecular entity. The commercial question is whether one pill can meaningfully replace two in a Korean market that already has several DPP-4 inhibitor plus statin FDCs and generic single-agent competitors at trivial cost.

Both active ingredients are approved and off-patent globally. Dapagliflozin was originally approved by the FDA in 2014 as Farxiga/Forxiga (AstraZeneca), with subsequent label expansions into heart failure and chronic kidney disease [2]. Rosuvastatin was approved in 2003 as Crestor and has been generic in the US since 2016 [3]. CMG190303 is a novel formulation rather than a new chemical entity, so the regulatory bar is essentially bioequivalence plus clinical additivity. No FDA breakthrough, fast-track, orphan, or priority-review designations apply, because CMG Pharmaceutical is running this as a program under South Korea's Ministry of Food and Drug Safety (MFDS) aimed at the domestic market first. Fixed-dose combinations of established metabolic drugs are a routine post-patent lifecycle strategy in South Korea, where reimbursement favors single-pill regimens. NCT06772168 is currently recruiting, sponsored by CMG Pharmaceutical Co. Ltd, with a target of 240 patients, a start date of 19 April 2024, and a listed primary completion date of 1 February 2027 [1]. No formal filing timeline has been disclosed by the sponsor.

Two separate, well-worn mechanisms in one pill. Dapagliflozin blocks SGLT2, a sodium-glucose cotransporter in the kidney that normally reabsorbs about 90% of the glucose the kidneys filter out. Block it and glucose spills into urine, dropping HbA1c by roughly 0.5 to 1% and pulling water and sodium with it, which is why SGLT2 inhibitors also lower blood pressure and cut heart-failure hospitalizations by around 30% independent of glucose control [4]. Rosuvastatin blocks HMG-CoA reductase, the liver enzyme that makes cholesterol. Less production leads to more LDL receptors on liver cells and, per the FDA-approved rosuvastatin label, roughly 45% LDL reduction at 5 mg, 52% at 10 mg, 55% at 20 mg, and 63% at 40 mg [9], which translates to a well-established reduction in cardiovascular events (JUPITER, 20 mg dose, ~50% LDL reduction and 44% relative reduction in the composite CV endpoint) [5]. Both mechanisms are ironclad: SGLT2 inhibition is validated by five approved drugs and multiple outcomes trials, and statin therapy has decades of hard-endpoint data. The combination premise is straightforward. Diabetics with dyslipidemia (which is most of them) are already prescribed both classes, and pill burden hurts adherence. Combining them into one tablet does not require novel biology, only formulation work and a pharmacokinetic demonstration that neither drug interferes with the other. Preclinical formulation feasibility for a dapagliflozin plus rosuvastatin single-tablet FDC has already been published in the Korean pharmaceutics literature [11].

NCT06772168 is a Phase 3, recruiting trial in 240 patients with type 2 diabetes and dyslipidemia, sponsored by CMG Pharmaceutical Co. Ltd, running across multiple Korean sites. The registry describes a three-arm, placebo-controlled design: CMG190303 (dapagliflozin plus rosuvastatin FDC), rosuvastatin plus dapagliflozin-placebo, and dapagliflozin plus rosuvastatin-placebo. There are two co-primary endpoints, both at 24 weeks: change in HbA1c from baseline versus the rosuvastatin-monotherapy arm, and change in LDL-C from baseline versus the dapagliflozin-monotherapy arm [1]. This is the standard 'factorial-lite' design used to demonstrate that each active ingredient in the FDC delivers its expected effect on its own biomarker, satisfying MFDS clinical-additivity requirements. Specific mg strengths of the dapagliflozin and rosuvastatin components have not been disclosed in the public registry entry; the study protocol likely uses the most-prescribed Korean strengths (dapagliflozin 10 mg plus a rosuvastatin dose in the 5-20 mg range), but this should be confirmed against the sponsor's IND filing before assuming interchangeability with any specific single-agent dose. n=240 is small but adequate for an HbA1c endpoint where dapagliflozin's effect size is well-characterized (approximately 0.7% HbA1c reduction with tight variance). The trial is not powered or designed to establish new cardiovascular outcomes: it exists to satisfy regulators that the FDC works like the two components taken concurrently. Enrollment progress against target has not been publicly reported.

Our model estimates a 13% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 53%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk centers on a pharmacokinetic interaction that reduces exposure of either component below therapeutic thresholds, though the two drugs are already co-prescribed in clinical practice with no meaningful known interaction. Safety risks are the class effects of each component. SGLT2 inhibitors carry a small but real risk of genitourinary infections and euglycemic diabetic ketoacidosis (a rare but serious buildup of acid in the blood that can occur even when blood sugar looks normal, driven by shifted fuel metabolism on SGLT2 inhibition), plus (for canagliflozin specifically, less so dapagliflozin) lower-limb amputation and fracture signals [7]. Rosuvastatin carries the standard statin risks of myopathy, transaminase elevation, and a modest increase in new-onset diabetes: meta-analysis of 13 statin trials reported roughly a 9% odds increase in incident T2D [10], and JUPITER specifically documented a ~25% relative increase in physician-reported T2D on rosuvastatin 20 mg [5]. That is clinically small in absolute terms but ironic in a patient who is already on dapagliflozin for diabetes. Execution risk is bigger than either: CMG Pharmaceutical (KRX: 058820, roughly $95M market cap, ~220 employees) is a small Korean specialty pharma without a track record of global filings, and their pipeline suggests domestic-market focus [12]. Commercial risk is the largest concern. Even if approved, CMG190303 competes against generic dapagliflozin plus generic rosuvastatin taken separately at trivial cost, plus the broader Korean FDC market for cardiometabolic combinations. Payers and providers need a reason to switch beyond convenience.

Watch this as a marker of Korean specialty pharma FDC activity, not as a value-creating clinical asset. The mechanistic case is closed. SGLT2 inhibition and statin therapy both work, and combining them in one pill will produce the expected additive effect on HbA1c and LDL. The relevant question is commercial: whether CMG Pharmaceutical secures MFDS approval, and whether they carve out share in a crowded Korean cardiometabolic FDC market that already includes several DPP-4 inhibitor plus statin combinations (for example, LG Chem's gemigliptin plus rosuvastatin, backed by published PK-equivalence work [11]). At time of writing, no public MFDS listing was found for a directly comparable dapagliflozin plus rosuvastatin FDC already on the Korean market, which suggests CMG190303 could be first-mover in that specific class combination if it clears bioequivalence and additivity. Given the trial's 19 April 2024 start and 1 February 2027 listed primary completion, top-line 24-week data plausibly reads out in H1 2027, with MFDS filing another ~6-12 months later if enrollment tracks and PK additivity holds. If CMG demonstrates any PK interaction that meaningfully reduces dapagliflozin or rosuvastatin exposure, the program dies. If bioequivalence holds and the co-primary endpoints are met, expect routine MFDS approval and modest revenue. This is not a competitive threat to AstraZeneca's Farxiga franchise, which posted approximately $7.7B in 2024 product sales driven by heart-failure and CKD label expansion [8], nor to the branded or generic statin market. The more interesting adjacent question is which US or EU generics manufacturer eventually files an equivalent FDC once formulation strategy is proven.

not_a_section